Eli Lilly (LLY) is going after two more drug compounders that continue to make and sell copies of its weight loss drug despite a March court order against it, multiple media outlets reported Tuesday.
The company's latest lawsuits were filed against Strive Pharmacy and Empower Clinic Services, Reuters reported. The company is demanding that compounders stop selling products with tirzepatide, the active ingredient in its weight loss and diabetes drugs Zepbound and Mounjaro.
Lilly had filed lawsuits against over two dozen medical spas, wellness centers, and compounding pharmacies, according to the report.
The company also plans to send around 50 cease-and-desist letters asking compounders and telehealth companies to confirm by April 8 that they have stopped manufacturing and selling all forms of compounded tirzepatide, Bloomberg reported.
Lilly did not immediately reply to a request for comment from MT Newswires.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。